Efficacy, Safety and PK of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis
Status:
Not yet recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
The study is an extension to the study StrongMoxi NCT04056325 and entails modifications based
on the outcome of NCT04056325 part A.
The study is a phase 3, double-blinded and randomized clinical trial conducted in Cambodia.
It aims at providing evidence on efficacy, safety and pharmacokinetic measures of 8 mg of
moxidectin compared to 200 μg/kg ivermectin in adults infected with S. stercoralis. The
efficacy of the treatment will be assessed by collecting three stool samples once
per-treatment and once 21-28 days post-treatment. The stool samples will be analyzed by a
quantitative duplicate Baermann assay.
Phase:
Phase 3
Details
Lead Sponsor:
Jennifer Keiser
Collaborator:
National Centre for Parasitology, Entomology and Malaria Control, Cambodia